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ABSTRACT
Background: Dietary sugars have been suggested as a cause of
obesity, several chronic diseases, and a range of cardiometabolic
risk factors, but there is no convincing evidence of a causal relation
between sugars and risk factors other than body weight.
Objective: We conducted a systematic review and meta-analysis of
randomized controlled trials that examined effects of the modifica-
tion of dietary free sugars on blood pressure and lipids.
Design: Systematic searches were conducted in OVID Medline,
Embase, Scopus, Cumulative Index to Nursing and Allied Health
Literature, and Web of Science databases (to August 2013) to identify
studies that reported intakes of free sugars and at least one lipid or blood
pressure outcome. The minimum trial duration was 2 wk. We pooled
data by using inverse-variance methods with random-effects models.
Results: A total of 39 of 11,517 trials identified were included; 37
trials reported lipid outcomes, and 12 trials reported blood pressure
outcomes. Higher compared with lower sugar intakes significantly
raised triglyceride concentrations [mean difference (MD): 0.11
mmol/L; 95% CI: 0.07, 0.15 mmol/L; P, 0.0001], total cholesterol
(MD: 0.16 mmol/L; 95% CI: 0.10, 0.24 mmol/L; P , 0.0001), low-
density lipoprotein cholesterol (0.12 mmol/L; 95% CI: 0.05, 0.19
mmol/L; P = 0.0001), and high-density lipoprotein cholesterol
(MD: 0.02 mmol/L; 95% CI: 0.00, 0.03 mmol/L; P = 0.03). Sub-
group analyses showed the most marked relation between sugar
intakes and lipids in studies in which efforts were made to ensure
an energy balance and when no difference in weight change was
reported. Potential explanatory factors, including a weight change,
in most instances explained ,15% of the heterogeneity between stud-
ies (I2 = 36–75%). The effect of sugar intake on blood pressure was
greatest in trials $8 wk in duration [MD: 6.9 mm Hg (95% CI: 3.4,
10.3 mm Hg; P , 0.001) for systolic blood pressure and 5.6 mm Hg
(95% CI: 2.5, 8.8 mm Hg; P = 0.0005) for diastolic blood pressure].
Conclusions: Dietary sugars influence blood pressure and serum
lipids. The relation is independent of effects of sugars on body
weight. Protocols for this review were registered separately for
effects of sugars on blood pressure and lipids in the PROSPERO
International prospective register of systematic reviews as PROS-
PERO 2012: CRD42012002379 and 2012: CRD42012002437, re-
spectively. Am J Clin Nutr doi: 10.3945/ajcn.113.081521.
INTRODUCTION
Dietary sugars have been suggested as a cause of obesity,
several chronic diseases, and a range of cardiometabolic risk
factors (1). The association between free sugars and dental caries,
although attenuated by fluoride, has been established beyond
reasonable doubt (2), and a recent meta-analysis has confirmed
the relation between sugar intake and body weight (3). The effect
of dietary sugars on weight appears to result from the extent to
which increasing or decreasing intakes in free-living individuals
influence energy intakes because no change in weight is apparent
when proportions of total energy derived from sugar are altered in
the context of strict energy balance. These observations appear to
apply regardless of whether sugars are consumed in a liquid (eg,
sugar-sweetened beverages) or solid form (3). There is no con-
vincing evidence of a causal relation between sugars and other
disease outcomes; hence, there has been a high degree of interest of
effects on blood pressure, blood lipids, urate, and, most recently,
hepatic lipidmetabolism and deposition (4, 5). An appreciable body
of data is are available that relate to effects of sugars on blood
pressure and lipids. In this article, we report a systematic review and
meta-analysis of randomized controlled trials that compared
higher with lower dietary free-sugar intakes in adults or children
free of acute illnesses, and reported fasting lipid or blood pressure
outcomes. Because our aim was to provide an indication of what
might be achieved by population changes in intake of dietary
sugars, we included studies in which energy intakes were not
strictly controlled as well as controlled feeding studies.
METHODS
Search strategy
Separate electronic searches were conducted to identify ran-
domized trials related to effects of dietary sugars on blood lipids and
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blood pressure in humans according to Cochrane Collaboration
guidelines (6). OVID Medline (http://www.nlm.nih.gov/bsd/
pmresources.html) and Embase (http://www.embase.com/), Scopus
(www.scopus.com), Web of Science (http://thomsonreuters.com/
web-of-science/), and the Cumulative Index to Nursing and Allied
Health Literature (http://www.ebscohost.com/academic/the-cinahl-
database) were searched for English-language trials published be-
tween 1960 and August 2013. We applied a modified search
strategy on the basis of Cochrane Collaboration methods to identify
randomized controlled trials (6). Gray literature databases including
Bioline, Clinicaltrials.gov, Directory of Open Access Journals,
SCIRUS, OpenDOAR, OpenGrey, Google, and DocuTicker were
also searched. Hand searches of reference lists of included studies
and published meta-analyses were also undertaken. See Online
Supplementary Material under “Supplemental data” in the online
issue for the OVID Medline search strategy used.
Study selection
Two reviewers assessed titles and abstracts of all identified
studies. Discrepancies in opinion as to whether a study should be
included for a full review were adjudicated by a third reviewer. A
similar process was undertaken to determine which studies
should be included in the formal analysis.
We included randomized trials, including crossover trials,
parallel trials, and cluster-randomized trials with a duration .2
wk, which compared dietary interventions intended to alter in-
take of sugar (sucrose) or other free sugars in one arm compared
with another arm of the study. The term free sugars refers to all
monosaccharides and disaccharides added to foods by the
manufacturer, cook, or consumer plus sugars naturally present in
honey, syrups, and fruit juices (7).
Trials that involved direct comparisons, behavioral in-
terventions, or multifactorial lifestyle interventions in which effects
of sugars could be analyzed separately from other diet or lifestyle
factors were included. Comparison groups could include a control
diet (on the basis of usual or unmodified dietary intakes) or an
intervention in which sugar intake was quantifiably different from
sugar intake in the experimental group. Animal and observational
studies were excluded. Studies were required to report differences
between treatment groups in intake of free sugars or intake of
a component of total sugars (expressed in absolute amounts or
a percentage of the total energy) and at least one measure of blood
pressure [systolic blood pressure (SBP)4, diastolic blood pressure
(DBP), or average blood pressure] or one measure of blood lipids
(triglycerides; total, LDL, or HDL cholesterol). Participants in-
cluded adults and children free from acute illness, but subjects
with diabetes or other noncommunicable diseases in whom con-
ditions were regarded as stable could be included. Trials could
include studies in which participants in the intervention arm were
advised to either increase or decrease free sugars or foods and
drinks that contained sugars. We included both trials in which
there was an isocaloric substitution of sugars with other forms of
carbohydrate to control weight and studies in which there was no
strict control of energy intake.
Data extraction and quality assessment
Data extraction and a validity assessment were carried out
independently by 2 reviewers, and any discrepancies were re-
solved by discussion with a third reviewer. Data that were related
to participant characteristics, study settings and designs, out-
comes, exposures or interventions, and potential effect modifiers,
such as the degree of weight loss, were extracted by using
a piloted data-extraction form. For outcome data, we extracted
data related to the difference in changes during the intervention
and the SE, 95% CI, or P value for the mean difference (MD).
Cochrane Collaboration criteria (8) were used to examine the
validity and risk of bias of each trial including sequence gen-
eration, blinding of participants, personal and outcome asses-
sors, completeness of outcome data, and selective outcome
reporting. Additional review-specific criteria included whether
studies were funded by industries with potential vested interests.
Statistical analysis
Individual trial data for each outcome measure were pooled to
obtain estimates for MDs in each outcome measure between
intervention and control groups with Review Manager (RevMan)
5.1 software (9) by using the generic inverse-variance method
(10) with DerSimonian and Laird random-effects models to
account for heterogeneity that could not be explained by dif-
ferences in study characteristics (10).
Estimates for the SE of differences in means for treatment
groups in crossover studies were derived from reported P values
when the SEM of the MD was not reported. If P values were
reported simply as not significant, a conservative estimate of P =
0.5 was imputed. Adjustment was made if the imputed P value
produced a very small or large SE that resulted in a dispropor-
tionate weighting in meta-analyses.
As in our previous systematic review of effects of sugars on
body weight (3), for main analyses, we have presented forest plot
analyses by subgroups relating to whether energy intake was
prescribed. One group included studies that attempted to achieve
an isocaloric replacement of sugars with other forms of carbo-
hydrate, which are referred to as isocaloric trials. The other group
included studies in which participants in the intervention arm
were advised to decrease or increase sugars or foods and drinks
that contained sugars. Although such advice was generally ac-
companied by the recommendation to increase or decrease
other forms of carbohydrate, there was no strict attempt at weight
control. In some of these trials, some foods or drinks were provided
to participants. These are referred to as ad libitum trials. Additional
subgroup analyses involved the examination of data according to
whether weight changes differed in intervention and control
groups. An additional post hoc analysis of ad libitum trials ex-
amined the effect on outcomes of whether sugars were reduced or
increased relative to usual intakes in the intervention group.
The heterogeneity of studies was assessed by using a combi-
nation of measures. We ascertained visually whether CIs of each
study in the forest plot overlapped. The chi-square test and I2
statistics were used to quantify heterogeneity (10). We con-
ducted metaregression analyses [with Stata/IC 11.2 software for
Mac (StataCorp)] to further examine effects of prespecified
explanatory factors, including weight change, diabetes status,
metabolic syndrome status, and study design (crossover- or
4Abbreviations used: DBP, diastolic blood pressure; MD, mean difference;
SBP, systolic blood pressure.
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parallel-designed trials), and the study duration on outcome
variables. Sensitivity analyses were conducted to examine the
effect of study quality by excluding trials considered to have




A total of 11,514 articles were initially identified after elec-
tronic searching. After deduplication and the exclusion of clearly
irrelevant articles, 102 articles remained for which full-text pa-
pers were obtained for detailed inspection. Thirty-eight studies
were considered to meet the inclusion criteria. Hand searches
through article reference lists identified an additional 2 articles
that met the inclusion criteria. In total, 40 studies were included in
the systematic review and meta-analysis involving 1699 subjects
(1217 subjects in parallel-designed trials and 482 subjects in
crossover-designed trials) (11–51). Of these studies, 39 trials
reported lipid outcomes (11–14, 16–20, 22–51), and 12 trials
reported blood pressure outcomes (11–22). The study iden-
tification process is shown in Figure 1, and characteristics of
included studies are described in Table 1. See Online Supple-
mentary Table 1 under “Supplemental data” in the online issue
for a description of the 62 excluded experimental trials.
Lipids
Of included trials, 38 studies reported on outcomes for tri-
glycerides (n = 1660 subjects) (11–14, 16–20, 22–49, 51), 36
studies reported on total cholesterol (n = 1596) (11–14, 17–20,
22–34, 36–44, 46–50), 22 studies reported on LDL cholesterol
(n = 1395) (11–14, 17, 19, 20, 22, 24–26, 33, 34, 36–38, 40, 42,
43, 46, 49), and 29 studies reported on HDL cholesterol (n =
1515) (11–14, 17–20, 22, 24–26, 28, 29, 31, 33, 34, 36–40, 42–
44, 46, 48, 49). A total of 28 trials involved a crossover design
(11–14, 16, 17, 19, 23, 25–32, 34–38, 40–42, 46–49), 16 trials
involved interventions for which energy intakes were not strictly
controlled (11, 18–20, 24, 28, 36, 38, 39, 43–45, 47–49, 51), and
11 trials had durations .8 wk (18, 20, 24, 31, 33, 37, 39, 43–45,
51). Participants included adults described as being of healthy
normal weight (11, 12, 18, 30, 40, 41, 46, 47, 50, 51) or over-
weight (22, 33, 36, 43–46, 51) or with various cardiovascular risk
factors (14, 20, 23, 27, 42, 44) or gallstones (49) or adults with
diabetes (13, 16, 24–26, 28, 29, 31, 34, 37–39, 48) (Table 1).
The overall mean effect of higher sugars was 0.11 mmol/L
(95% CI: 0.07, 0.15 mmol/L; P, 0.0001) for triglycerides, 0.16
mmol/L (95% CI: 0.09, 0.24 mmol/L; P , 0.0001) for total
cholesterol, 0.12 mmol/L (95% CI: 0.05, 0.19 mmol/L; P =
0.001) for LDL cholesterol, and 0.02 mmol/L (95% CI: 0.00,
0.03 mmol/L; P = 0.02) for HDL cholesterol (Figures 2–5). The
effect of altering sugar intake on triglyceride concentrations was
similar in studies in which an attempt was made to achieve
isocaloric comparisons and studies in which ad libitum diets
were consumed (Figure 2). For total, LDL, and HDL cholesterol
(Figures 3–5), the effect of higher sugar intakes was significant
only in isocaloric trials; however, the differences between sub-
group effect estimates were NS.
Subgroup analyses according to whether weight change oc-
curred (see online supplementary Figures 1–4 under “Supple-
mental data” in the online issue) showed that the greatest effects
of sugars on each outcome occurred in trials in which no dif-
ference in weight change was reported between intervention and
control groups. Similar, less striking, but still significant trends
were apparent for triglycerides and total cholesterol when we
FIGURE 1. PRISMA flow diagram illustrating the study identification and selection process. PRISMA, Preferred Reporting Items for Systematic Reviews
and Meta-Analyses.
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considered trials in which weight gain was reported in in-
tervention compared with control groups. In contrast, the effect
of sugars on triglycerides and total cholesterol was attenuated
and no longer significant when we considered trials in which
greater weight reduction was reported in higher-sugar groups.
See online supplementary Figures 5–8 under “Supplemental
data” in the online issue for post hoc subgroup analyses ac-
cording to whether the intervention group involved a reduction
or increase in sugar intakes relative to usual intakes. Eleven
trials involved increased sugar intakes, and 2 trials involved
reduced sugar intakes in intervention relative to control arms.
Four trials involved an increase in sugars in one arm and a de-
crease in sugars in the comparison arm. The greatest effect of
higher sugar intakes on lipids was shown in trials that compared
an increase in sugars in one arm compared with a decrease in
sugars in the other arm, but this effect was only significant for
triglycerides [MD: 0.17 mmol/L (95% CI: 0.06, 0.27 mmol/L;
P = 0.001) for triglycerides, 0.14 mmol/L (95% CI: 20.13,
0.41mmol/L; P = 0.31) for total cholesterol, and 0.16 mmol/L
(95% CI: 20.10, 0.42 mmol/L; P = 0.23) for LDL cholesterol].
The effect of sugars was not significant for other trial types.
Heterogeneity in trials was high and significant for each
outcome (I2 = 73% for triglycerides, 74% for total cholesterol,
73% for LDL cholesterol, and 36% for HDL cholesterol).
Little of the heterogeneity for triglyceride and total- and
LDL-cholesterol outcomes (,15%) was explained by differences
in study designs, study durations, diabetes status, or types of
sugars compared. There was a positive effect of the difference in
sugar intakes between intervention and control groups on LDL
cholesterol only (P = 005); this factor explained 54% of between-
study heterogeneity. The effect of sugars on total cholesterol was
reduced in trials $8 compared with ,8 wk duration (P = 0.009),
FIGURE 2. Meta-analysis of weighted mean (95% CI) differences (mmol/L) in effects on blood triglyceride concentrations in randomized controlled trials
that compared higher with lower free-sugar intakes on blood triglyceride concentrations by subgroups relating to energy intake prescription. Black diamonds
denote the weighted mean difference for the two subgroup analyses and the overall effect. For individual studies, the black square denotes the mean study
effect, and the bars represent the 95% CI. Data were estimated by using generic IV methods with a DerSimonian and Laird random-effects model. IV, inverse
variance.
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but this factor explained only 14% of the heterogeneity. See on-
line supplementary Table 2 under “Supplemental data” in the
online issue for results of meta-regression analyses.
Blood pressure
Twelve trials reported blood pressure outcomes (n = 324) (11–
22). Participants included those described as healthy but over-
weight (19–22), hyperinsulinemic (14), with type 2 diabetes (13,
16), or with the metabolic syndrome (20) (Table 1).
There was no significant effect of higher sugar intakes on SBP
overall (MD: 1.1 mm Hg; 95% CI: 21.0, 3.2 mm Hg; P = 0.32);
however, there was significant heterogeneity in results of in-
dividual trials (P = 0.0005, I2 = 67%) (Figure 6). Subgroup
analyses showed a significant interaction with the study duration
but no significant difference between isocaloric and ad libitum
trials (P = 0.0002). In trials of ,8 wk duration, there was no
evidence of an effect of a higher-sugar diet on SBP, whereas in 3
trials of .8 wk duration (18, 20, 21), the mean effect was 6.9
mm Hg (95% CI: 3.4, 10.3 mm Hg; P , 0.0001) (see online
supplementary Figure 9 under “Supplemental data” in the online
issue). Two of these longer-term trials resulted in significantly
higher body weight after the higher-sugar intervention (20, 21).
Poppitt et al (20) showed that a higher-sugar intervention re-
sulted in a 0.28-kg weight loss compared with a 4.25-kg loss in
the lower-sugar diet group, and Raben et al (21) reported an
increase in weight with the high-sugar diet and a decrease in
weight with the low-sugar diet.
Heterogeneity was also largely explained by the trial design
because 8 of 9 short-term trials had a crossover design (11–17,
19). See online supplementary Table 2 under “Supplemental
data” in the online issue for findings of the meta-regression that
explored causes for the heterogeneity.
A higher sugar intake was associated with significantly greater
DBP of 1.4 mm Hg (95% CI: 0.3, 2.5 mm Hg; P = 0.02) overall
(Figure 7). This effect was greater for ad libitum trials (MD: 3.7
FIGURE 3. Meta-analysis of weighted mean (95% CI) differences (mmol/L) in effects on total cholesterol concentrations in randomized controlled trials
that compared higher with lower free-sugar intakes on blood triglyceride concentrations by subgroups relating to energy intake prescription. Black diamonds
denote the weighted mean difference for the two subgroup analyses and the overall effect. For individual studies, the black square denotes the mean study
effect, and the bars represent the 95% CI. Data were estimated by using generic IV methods with a DerSimonian and Laird random-effects model. IV, inverse
variance.
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mm Hg; 95% CI: 0.3, 7.1 mm Hg; P = 0.03). There was a sig-
nificant interaction with the study duration (P = 0.002) with
a stronger association in trials of .8 wk duration (18, 20, 21) of
5.6 mm Hg (95% CI: 2.5, 8.8 mm Hg; P = 0.0005) (see online
supplementary Figure 10 under “Supplemental data” in the on-
line issue).
Subgroup analyses according to whether a weight change
occurred (see online supplementary Figures 11–12 under
“Supplemental data” in the online issue) showed a significant
effect of sugars on both SBP (MD: 2.7 mm Hg; 95% CI: 0.2, 5.2
mm Hg; P = 0.03) and DBP (MD: 3.2 mm Hg; 95% CI: 0.6, 5.77
mm Hg; P = 0.01) in 2 trials in which no difference in weight
change was reported between intervention and control groups.
However, subgroup differences were not statistically significant
(P = 0.61 for SBP and 0.37 for DBP).
See online supplementary Figures 13–14 under “Supple-
mental data” in the online issue for post hoc subgroup analyses
according to whether the intervention group involved a re-
duction or increase in sugar intakes relative to usual intakes.
There was a significant effect of higher sugar intakes on blood
pressure only in 2 trials that compared an increase in sugars in
one arm compared with a decrease in sugar in the other arm
(MD: 6.0 mm Hg; 95% CI: 1.7, 10.2 mm Hg; P = 0.006 for SBP;
and 4.9 mm Hg; 95% CI: 1.2, 8.6 mm Hg; P = 0.01 for DBP).
No trials were identified that involved reduced sugar intakes in
the intervention arm compared with usual sugar intakes in the
comparison arm.
Risk of bias
See online supplementary Figures 15 and 16 under “Supple-
mental data” in the online issue for a summary of risk of bias
assessment. Although the blinding of participants and re-
searchers to treatment was not explicitly stated in most studies,
risk of bias was considered low in crossover trials because
participants completed both high- and low-sugar interventions.
Moreover, the blinding to treatment was not possible in studies
that involved free-living participants and in which the in-
tervention involved a provision of dietary advice.
Fourteen studies included in lipid analyses were considered at
high risk of bias because of the reporting of nonsignificant
findings as “NS” or “not significant,” and thus, we were required
to impute a P value to generate an estimate for the SE (11–14,
16, 27–31, 37, 38, 47, 49). However, the omission of these
studies would have resulted in an overestimate of effects of
higher sugar intakes on lipid outcomes. Fourteen studies re-
ceived financial support from the sugar industry (12, 13, 17, 20,
25, 26, 33–36, 43, 46, 48, 51). We considered the risk of bias
from such funding as unclear. The exclusion of these studies
from the analysis strengthened the effect of sugars on tri-
glycerides (MD: 0.19 mmol/L; 95% CI: 0.11, 0.27 mmol/L; P,
0.0001), total cholesterol (MD: 0.18 mmol/L; 95% CI: 0.05,
0.31 mmol/L; P = 0.008), and HDL cholesterol (MD: 0.03
mmol/L; 95% CI: 0.00, 0.06 mmol/L; P = 0.03).
In trials included in blood pressure analyses, one study was
considered to be at high risk of bias because of the reporting of
FIGURE 4. Meta-analysis of weighted mean (95% CI) differences (mmol/L) in effects on LDL-cholesterol concentrations in randomized controlled trials that
compared higher with lower free-sugar intakes on blood triglyceride concentrations by subgroups relating to energy intake prescription. Black diamonds denote the
weighted mean difference for the two subgroup analyses and the overall effect. For individual studies, the black square denotes the mean study effect, and the bars
represent the 95% CI. Data were estimated by using generic IV methods with a DerSimonian and Laird random-effects model. IV, inverse variance.
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incomplete outcome data because there were substantially more
dropouts in the intervention than control groups (28% compared
with 8%, respectively) (22). Three crossover trials had no
washout period (13–15), and one trial received funding from
food-and sugar-manufacturing companies (22). Sensitivity
analyses that examined effects of the exclusion of studies with
potentially important biases did not alter the significance of the
association between higher sugar intakes and blood pressure.
The exclusion of the 5 studies that received funding from sugar
industries (12, 13, 17, 20, 22) strengthened associations between
sugars and SBP (MD: 7.6 mm Hg; 95% CI: 3.9, 11.2 mm Hg;
P , 0.001) and DBP (MD: 6.1 mm Hg; 95% CI: 2.6, 9.5 mm
Hg; P = 0.0006) in longer-term trials and overall for DBP (MD:
1.84 mm Hg; 95% CI: 0.1, 3.6 mm Hg; P = 0.04).
Publication bias
SEs for mean effects were imputed for 15 crossover studies
included in meta-analyses (11–14, 16, 27–31, 37, 38, 47–49)
whereby differences in effects on one or more outcomes of in-
terest between higher- and lower-sugar interventions were re-
ported simply as “not significant” and without an estimate of the
SEM difference. The resulting SE estimates lacked sufficient
precision to enable meaningful funnel plot analyses or statistical
tests for publication bias such as Egger’s test (8). However, the
inclusion of a relatively large number of trials that reported
nonsignificant effects suggested low risk of publication bias.
DISCUSSION
This systematic review and meta-analyses of randomized
controlled trials provides evidence that higher compared with
lower intakes of sugars are associated with increased concen-
trations of triglycerides, total and LDL cholesterol, and blood
pressure, although for SBP, this effect was only significant in
studies of a longer duration. The study duration was the only
important determinant of the heterogeneity in studies with regard
to blood pressure outcomes. When we considered lipid outcomes,
the significant heterogeneity in studies was not explained by any
of the potentially confounding variables. However, because 40%
of studies involved free-living individuals who consumed ad
libitum diets for which energy intakes were not strictly con-
trolled, and many of the trials that were intended to compare
isocaloric diets did not include adequate measures of compliance,
it seems likely that a varying adherence to dietary advice
explained at least some of the variation.
FIGURE 5. Meta-analysis of weighted mean (95% CI) differences (mmol/L) in effects on HDL-cholesterol concentrations in randomized controlled trials
that compared higher with lower free-sugar intakes on blood triglyceride concentrations by subgroups relating to energy intake prescription. Black diamonds
denote the weighted mean difference for the two subgroup analyses and the overall effect. For individual studies, the black square denotes the mean study
effect, and the bars represent the 95% CI. Data were estimated by using generic IV methods with a DerSimonian and Laird random-effects model. IV, inverse
variance.
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Because of the powerful association between adiposity and
both lipid and blood pressure (52–54) and the potential for
change in intakes of free sugars to influence body weight in free-
living individuals (3), it might be assumed that altered energy
intakes and weight loss explained the present set of observa-
tions. However, a subgroup analysis showed that, for trigly-
cerides and total and LDL cholesterol, the most-consistent
associations between higher intakes of sugars and higher con-
centrations were seen in studies in which attempts were made to
achieve an isocaloric exchange or when no difference in weight
change between interventions was reported. Higher triglyceride
concentrations were also observed in ad libitum studies and
when weight increases were reported with the higher-sugar in-
tervention. Effects of sugars on triglycerides appeared to be
FIGURE 7. Meta-analysis of weighted mean (95% CI) differences (mmol/L) in effects of diastolic blood pressure in randomized controlled trials that
compared higher with lower free-sugar intakes on blood triglyceride concentrations by subgroups relating to energy intake prescription. Black diamonds
denote the weighted mean difference for the two subgroup analyses and the overall effect. For individual studies, the black square denotes the mean study
effect, and the bars represent the 95% CI. Data were estimated by using generic IV methods with a DerSimonian and Laird random-effects model. IV, inverse
variance.
FIGURE 6. Meta-analysis of weighted mean (95% CI) differences (mmol/L) in effects of systolic blood pressure in randomized controlled trials that
compared higher with lower free-sugar intakes on blood triglyceride concentrations by subgroups relating to energy intake prescription. Black diamonds
denote the weighted mean difference for the two subgroup analyses and the overall effect. For individual studies, the black square denotes the mean study
effect, and the bars represent the 95% CI. Data were estimated by using generic IV methods with a DerSimonian and Laird random-effects model. IV, inverse
variance.
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attenuated in studies in which, for whatever reason, weight loss
occurred. In the absence of an important contribution of an
energy imbalance, the most likely explanation for the effect of
free sugars on blood pressure and lipids is in the fructose
component, which is present in sucrose (sugar), high-fructose
corn syrup, honey, and fruit (55).
Excessive intake of dietary fructose, particularly from sugar-
sweetened beverages, has been shown to increase hepatic fat
synthesis, which results in increased concentrations of circulating
triglycerides and cholesterol (1). In addition, unregulated hepatic
fructose metabolism may lead to increased urate synthesis. Urate
has been shown to decrease nitrous oxide synthesis and impairs
the function of endothelial cells resulting in vasoconstriction (1)
and may directly stimulate the renin-angiotensin system to in-
crease blood pressure (55, 56). Regardless of the precise
mechanism, high serum urate has been linked with hypertension
and increased cardiovascular risk (57).
Our findings are compatible with epidemiologic observations
and experimental studies in animals that have consistently
suggested an association between high dietary sugar or fructose
intakes and increased lipids (triglycerides), blood pressure, body
fat, and cardiovascular mortality (1, 18, 58–73).
However, our findings contrast with findings of 2 recent
systematic reviews and meta-analyses that specifically examined
metabolic effects of fructose consumption compared with of
other carbohydrates (including other sugars), which suggested no
unique lipid- or blood pressure–raising effects of fructose unless
intakes were very high (.100 g/d) (74) or fructose was ex-
changed for starch (75). This difference may have resulted be-
cause we did not include studies that exchanged fructose for
other sugars because our aim was to examine the effect of total
free sugars to further inform recommendations. Most trials in-
cluded in our meta-analysis involved different intakes of sugar
(sucrose) and other monosaccharides and disaccharides, or “free
sugars” as defined by the WHO (7), in control and intervention
arms. We examined effects of total sugars as well as various
subcategories of sugars but showed no difference by the type of
sugars.
Although effects of sugars on lipids and blood pressure are
relatively modest, a reduction of intake is likely to have public
health relevance, especially in the context of the modification of
several risk factors that have synergistic effects in terms of
cardiovascular risk (76). Risk of cardiovascular disease was
increased by 6% in men and 12% in women for each 0.2-mmol/L
increase in triglyceride concentrations in a meta-analysis of
prospective studies by Hokanson and Austin (77), whereas risk of
stroke was shown to be reduced by 4.5% for each 0.1-mmol/L
reduction in LDL cholesterol in a meta-analysis by Labreuche
et al (78). The difference we observed in HDL cholesterol was
very small and of questionable significance. A meta-analysis by
Neal et al (79) suggested that modest reductions in blood pressure
(range: 3-6 mmHg SBP and 1-4 mmHg DBP) over the long term
were associated with reductions in risk of stroke, coronary heart
disease, cardiovascular events, and mortality in the order of
20–30%. Although an understanding of the extent to which
changes in energy intake and body weight influence the effect of
sugars on cardiometabolic risk is of inherent interest, individual
and public health benefits that might be expected to accrue from
the reduction in intake of added sugars does not depend on an
understanding of the mechanism.
A strength of this review was that it involved a comprehensive
approach to identifying relevant English-language studies, and
included data from all relevant studies regardless of the exper-
imental design. The observed heterogeneity appears to be in-
sufficient to detract from the overall conclusion that free sugars
have the potential to adversely influence lipid concentrations and
blood pressure. Crossover trials, which are generally considered
to have a more-robust design than that of parallel trials because of
reduced intraparticipant variability (80) constituted a significant
body of data to the overall analysis. In some studies, effects of
sugar intakes on blood pressure or lipid outcomes were reported
as nonsignificant with insufficient data reported to accurately
calculate the SEM difference. We felt it was important to include
these studies because they represented a large body of evidence
for our analysis. For these studies, we approximated the SEM
difference rather than omitting data. The effect of doing so was to
give a more-conservative estimate of effects of sugars on blood
pressure and lipids, which enhanced our confidence in the
findings (81). The inclusion of both controlled trials and studies
that primarily involved the modification of free sugars without
strict control of total food intake enabled the additional un-
derstanding of mechanisms as well as the strengthening of nu-
tritional recommendations regarding free-sugar intakes. Our
previous review (3) suggested that advice to reduce sugars
without specifying a replacement energy resulted in a decrease in
body weight. This study has shown benefit in terms of lipids and
blood pressure regardless of whether an energy balance was
achieved.
Limitations of these findings were those inherent to the pri-
mary research on which they were based, notably the inadequacy
of dietary intake data, variation in the nature and quality of the
dietary intervention, small numbers of participants, and relatively
short study duration (,8 wk) of many trials. The limited number
of ad libitum studies that involved a reduction in sugar intakes in
the intervention arm relative to usual intakes in the control arm
(see online supplementary Figures 5–8, 13, and 14 under
“Supplemental data” in the online issue) precluded definitive
conclusions regarding this subgroup.
In conclusion, this systematic review and meta-analyses
provide evidence that dietary free sugars influence blood pressure
and serum lipids independently of the effect of sugars on body
weight. Although effects of sugars on blood pressure and lipids
are relatively modest, our findings support the idea that reducing
free-sugar intakes might be expected to reduce blood pressure
and serum lipids.
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